Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases

Clinical Neurology and Neurosurgery

Volumn 112, Issue 6, 2010, Pages 467-469

  Nadeau, Janel O ^a   Bhibhatbhan, Arunee ^a   McDougall, David ^a   Toth, Cory ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Guillain Barre syndrome; Intravenous immunoglobulin; Myasthenia gravis; Neuromuscular disorders

Indexed keywords

ALBUMIN; CYTOMEGALOVIRUS ANTIBODY; GAMAIMUNE; GLUCOSE; GLYCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; ISOLEUCINE; MALTOSE; NICOTINAMIDE; PROLINE; SUCROSE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUROMUSCULAR DISEASE; PATIENT CARE; PREVALENCE; PRURITUS; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY HEALTH CARE; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CHEMISTRY, PHARMACEUTICAL; FEMALE; FREEZE DRYING; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A; IMMUNOGLOBULINS, INTRAVENOUS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77952885089     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2010.02.008     Document Type: Article

References (20)

1. Bertorini T.E., Nance A.M., Horner L.H., Greene W., Gelfand M.S., and Jaster J.H. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 19 (1996) 388-391
2. Bruton O.C. Agammaglobulinemia. Pediatrics 9 (1952) 722-728
3. Linker R.A., and Gold R. Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 21 (2008) 358-365
4. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 (1981) 1228-1231
5. Gold R., Stangel M., and Dalakas M.C. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3 (2007) 36-44
6. Hughes R.A., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7 (2008) 136-144
7. Anonymous. NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 264 (1990) 3189-3193
8. Ferrero B., and Durelli L. High-dose intravenous immunoglobulin G treatment of myasthenia gravis. Neurol Sci 23 Suppl. 1 (2002) S9-24
9. Hanna K., Poulin-Costello M., Preston M., and Maresky N. Intravenous immune globulin use in Canada. Can J Clin Pharmacol 10 (2003) 11-16
10. Sinclair C.J., Brooks W., and Genereux M.G. Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. Biologicals 36 (2008) 256-262
11. Duhem C., Dicato M.A., and Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 97 Suppl. 1 (1994) 79-83
12. Sekul E.A., Cupler E.J., and Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121 (1994) 259-262
13. Stangel M., Kiefer R., Pette M., Smolka M.N., Marx P., and Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders-a prospective study. J Neurol 250 (2003) 818-821
14. Zinman L., Ng E., and Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68 (2007) 837-841
15. Tufan F., Kamali S., Erer B., Gul A., Inanc M., Ocal L., et al. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rheumatol 26 (2007) 1913-1915
16. Dalakas M.C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59 (2002) S13-21
17. Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease. Recent Pat Cardiovasc Drug Discov 3 (2008) 141-144
18. Caress J.B., Cartwright M.S., Donofrio P.D., and Peacock Jr. J.E. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 60 (2003) 1822-1824
19. Nydegger U.E., and Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 21 (1999) 171-185
20. Grillo J.A., Gorson K.C., Ropper A.H., Lewis J., and Weinstein R. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 57 (2001) 1699-1701